Biomarkers of Cognitive Decline among Normal Individuals: the BIOCARD cohort

正常个体认知能力下降的生物标志物：BIOCARD 队列

基本信息

批准号：
7943450
负责人：
MARILYN S. ALBERT
金额：
$ 61.49万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-01 至 2014-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7943450
关键词：
Advisory Committees Alzheimer&apos s Disease Area Arts Autopsy Baltimore Biological Markers Biometry Blood Blood specimen Brain Cerebrospinal Fluid Clinical Clinical Trials Cognition Cognitive Collaborations Communities Consensus Consent Data Data Analyses Databases Dementia Development Diagnosis Disease District of Columbia Enrollment Episodic memory Evaluation Family history of Funding Future Genetic Goals Hippocampus (Brain)Home visitation House Call Image Impaired cognition Impairment Individual Life Magnetic Resonance Imaging Measures Methods Modeling Neuropsychological Tests Office Visits Outcome Participant Radial Recording of previous events Research Research Personnel Resource Allocation Resources Risk Scientist Shapes Site Structure Techniques Telephone Testing Therapeutic Agents Time Washington base cognitive change cohort design experience follow-up interest member middle age mild neurocognitive impairment neuroimaging progression marker prospective public-private partnership research clinical testing response

项目摘要

This is a response to RFA # RFA-AG-09-002. The major goals of the proposal are to: (1) Identify biomarkers that are associated with progression from normal cognitive status to mild cognitive impairment (MCI) or dementia, with a particular focus on the dementia of Alzheimer's disease (AD) - these biomarkers may potentially include measures based on cognitive testing, magnetic resonance imaging (MRI), blood, or cerebrospinal fluid (CSF); (2) Determine which cross-sectional or longitudinal biomarker measures (taken alone or in combination) are the best predictors of progression from normal cognition to varying levels of cognitive dysfunction (i.e., MCI or AD); (3) Create a publicly accessible data base containing the clinical, cognitive, imaging, blood and CSF data - raw imaging data and samples of blood and CSF will also be available to investigators in the field, as appropriate. A team of investigators has been assembled at the study site with substantial experience in the clinical evaluation of older individuals, as well as expertise in the analysis of the biomarkers in question. Several external advisory groups will be assembled in order to provide guidance concerning the analysis of the data (particularly the CSF and blood samples, which are a non-renewable resource). In order to accomplish these goals we will: (1) complete a comprehensive clinical evaluation on as many prior participants in BIOCARD as possible in order to determine their current clinical and cognitive status - this will represent an approximate 10 year follow-up of the cohort; (2) initiate annual, longitudinal, clinical and cognitive evaluations on as many of these individuals as possible in order to complete a 15 year follow-up of the cohort by the end of the funding period; (3) complete analyses of the previously collected MRI scans, CSF samples and blood, using state-of-art techniques; (4) complete analyses of the relationship of the previously collected data to the current status of the subjects; and (5) provide these data to the scientific community through a publicly accessible database.

这是对RFA＃RFA-AG-09-002的回应。该提案的主要目标是：（1）确定生物标志物与从正常认知状况到轻度认知障碍（MCI）或痴呆症特别关注阿尔茨海默氏病（AD）的痴呆症 - 这些生物标志物可能可能包括基于认知测试，磁共振成像（MRI），血液或血液或脑脊液（CSF）；（2）确定哪种横截面或纵向生物标志物测量（采取单独或组合）是从正常认知到不同水平的进展的最佳预测指标认知功能障碍（即MCI或AD）；（3）创建一个包含临床的公共数据库，认知，成像，血液和CSF数据 - 原始成像数据以及血液和CSF的样本也将是适用于该领域的调查人员。一组调查员已在研究地点在老年人的临床评估方面具有丰富的经验，以及专业知识分析有关的生物标志物。将组建几个外部咨询小组提供有关数据分析的指导（尤其是CSF和血液样本，这是不可再生资源）。为了实现这些目标，我们将：（1）完成全面的临床对生物卡中尽可能多的先前参与者进行评估，以确定其当前的临床和认知状况 - 这将代表该队列的大约10年随访；（2）年度启动，对这些人的纵向，临床和认知评估，以便为了在资金期结束之前完成15年的随访；（3）对先前使用最先进的技术收集了MRI扫描，CSF样品和血液。（4）完成对先前收集的数据与受试者当前状态的关系的分析；（5）通过公开访问的数据库向科学界提供这些数据。